Cara Therapeutics | CARA




Peers Price Chg Day Year Date
Chugai Pharma 8,779.00 -419.00 -4.56% 31.94% Apr/03
Acadia Pharmaceuticals 22.20 -0.12 -0.54% 37.72% Apr/02
Cara Therapeutics 3.02 0.02 0.67% -79.66% Apr/02
Clal Biotechnology 30.90 0.60 1.98% -7.49% Mar/31
Compugen 655.80 18.00 2.82% 23.13% Mar/31
Cipla 1,192.40 -3.50 -0.29% -20.28% Apr/02
CSL 138.93 -3.24 -2.28% -46.08% Apr/02
Assertio Holdings 19.21 -0.67 -3.37% 87.51% Apr/02
Grifols 8.24 -0.01 -0.12% 15.89% Apr/02
Halozyme Therapeutics 64.49 -0.91 -1.39% 4.15% Apr/02

Indexes Price Day Year Date
USND 21879 38.23 0.18% 32.20% Apr/02
US2000 2530 17.67 0.70% 32.42% Apr/02

Cara Therapeutics traded at $3.02 this Thursday April 2nd, increasing $0.02 or 0.67 percent since the previous trading session. Looking back, over the last four weeks, Cara Therapeutics gained 23.35 percent. Over the last 12 months, its price fell by 79.66 percent. Looking ahead, we forecast Cara Therapeutics to be priced at 2.93 by the end of this quarter and at 2.67 in one year, according to Trading Economics global macro models projections and analysts expectations.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.